Murine models to study Clostridium difficile infection and transmission

Anaerobe

Volumn 24, Issue , 2013, Pages 94-97

  Lawley, Trevor D ^a   Young, Vincent B ^b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Disease; Microbiota; Spore; Transmission

Indexed keywords

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SPORE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE MODEL; HEALTH CARE FACILITY; INFECTION CONTROL; MICROFLORA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE;

CLOSTRIDIUM DIFFICILE; MURINAE;

ANTIBIOTIC-ASSOCIATED DIARRHEA; CLOSTRIDIUM DIFFICILE; DISEASE; MICROBIOTA; SPORE; TRANSMISSION;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DISEASE MODELS, ANIMAL; HUMANS; MICE;

EID: 84889097307     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2013.09.008     Document Type: Article

References (33)

1. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. New Engl J Med 2005, 353:2442-2449.
2. McDonald L.C., Killgore G.E., Thompson A., Owens R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353:2433-2441.
3. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
4. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis Off Publ Infect Dis Soc Am 2012, 55(Suppl.2):S88-S92.
5. Bartlett J.G., Onderdonk A.B., Cisneros R.L., Kasper D.L. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. JInfect Dis 1977, 136:701-705.
6. Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., Onderdonk A.B. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. NEngl J Med 1978, 298:531-534.
7. Fekety R., Silva J., Toshniwal R., Allo M., Armstrong J., Browne R., et al. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis 1979, 1:386-397.
8. Wilson K.H., Silva J., Fekety F.R. Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun 1981, 34:626-628.
9. Merrigan M.M., Sambol S.P., Johnson S., Gerding D.N. New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009, 33(Suppl.1):S46-S50.
10. Best E., Freeman J., Wilcox M. Models for the study of Clostridium difficile infection. Gut Microbes 2012, 3.
11. Pedron T., Sansonetti P. Commensals, bacterial pathogens and intestinal inflammation: an intriguing menage a trois. Cell Host Microbe 2008, 3:344-347.
12. Britton R.A., Young V.B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 2012, 20(7):313-319.
13. Antonopoulos D.A., Huse S.M., Morrison H.G., Schmidt T.M., Sogin M.L., Young V.B. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009, 77:2367-2375.
14. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011, 108(Suppl.1):4554-4561.
15. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008, 6:e280.
16. Cho I., Yamanishi S., Cox L., Methe B.A., Zavadil J., Li K., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
17. Wlodarska M., Willing B., Keeney K.M., Menendez A., Bergstrom K.S., Gill N., et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated citrobacter rodentium-induced colitis. Infect Immun 2011, 79:1536-1545.
18. Chen X., Katchar K., Goldsmith J.D., Nanthakumar N., Cheknis A., Gerding D.N., et al. Amouse model of Clostridium difficile-associated disease. Gastroenterology 2008, 135:1984-1992.
19. Reeves A.E., Theriot C.M., Bergin I.L., Huffnagle G.B., Schloss P.D., Young V.B. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes 2011, 2:145-158.
20. Lawley T.D., Clare S., Walker A.W., Goulding D., Stabler R.A., Croucher N., et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 2009, 77:3661-3669.
21. Lawley T.D., Clare S., Walker A.W., Stares M.D., Connor T.R., Raisen C., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
22. Reeves A.E., Koenigsknecht M.J., Bergin I.L., Young V.B. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 2012, 80(11):3786-3794.
23. He M., Sebaihia M., Lawley T.D., Stabler R.A., Dawson L.F., Martin M.J., et al. Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci U S A 2010, 107:7527-7532.
24. Kuipers E.J., Surawicz C.M. Clostridium difficile infection. Lancet 2008, 371:1486-1488.
25. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. JInfect Dis 2008, 197:435-438.
26. Figueroa I., Johnson S., Sambol S.P., Goldstein E.J., Citron D.M., Gerding D.N. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis Off Publ Infect Dis Soc Am 2012, 55(Suppl.2):S104-S109.
27. Deakin L.J., Clare S., Fagan R.P., Dawson L.F., Pickard D.J., West M.R., et al. Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 2012, 80:2704-2711.
28. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53:994-1002.
29. Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. JClin Gastroenterol 2010, 44:354-360.
30. Guerrero D.M., Nerandzic M.M., Jury L.A., Jinno S., Chang S., Donskey C.J. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. Am J Infect Control 2012, 40:556-558.
31. Vonberg R.P., Kuijper E.J., Wilcox M.H., Barbut F., Tull P., Gastmeier P., et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2008, 14(Suppl.5):2-20.
32. Lawley T.D., Croucher N.J., Yu L., Clare S., Sebaihia M., Goulding D., et al. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. JBacteriol 2009, 191:5377-5386.
33. Lawley T.D., Clare S., Deakin L.J., Goulding D., Yen J.L., Raisen C., et al. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol 2010, 76:6895-6900.